4//SEC Filing
Turner Kathy V 4
Accession 0001567619-23-003223
CIK 0000874716other
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 6:56 PM ET
Size
35.2 KB
Accession
0001567619-23-003223
Insider Transaction Report
Form 4
Turner Kathy V
Corporate Vice President
Transactions
- Exercise/Conversion
Common Stock
2023-02-14+210→ 7,150.849 total - Exercise/Conversion
Common Stock
2023-02-14+181→ 7,331.849 total - Exercise/Conversion
Common Stock
2023-02-14+86→ 7,579.949 total - Exercise/Conversion
Restricted Stock Unit
2023-02-14−93→ 793 total→ Common Stock (93 underlying) - Exercise/Conversion
Common Stock
2023-02-14+162→ 7,439.849 total - Tax Payment
Common Stock
2023-02-14$503.65/sh−293$147,569→ 7,379.849 total - Exercise/Conversion
Common Stock
2023-02-14$79.54/sh+2,000$159,080→ 9,379.849 total - Sale
Common Stock
2023-02-14$505.06/sh−1,000$505,059→ 8,379.849 total - Exercise/Conversion
Restricted Stock Unit
2023-02-14−86→ 886 total→ Common Stock (86 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right-to-buy)
2023-02-14−2,000→ 4,736 totalExercise: $79.54Exp: 2025-02-13→ Common Stock (2,000 underlying) - Exercise/Conversion
Common Stock
2023-02-14+93→ 7,672.849 total - Sale
Common Stock
2023-02-14$504.66/sh−313$157,959→ 8,066.849 total - Sale
Common Stock
2023-02-14$504.09/sh−577$290,861→ 7,489.849 total - Sale
Common Stock
2023-02-14$502.81/sh−110$55,310→ 7,379.849 total - Exercise/Conversion
Restricted Stock Unit
2023-02-14−210→ 1,315 total→ Common Stock (210 underlying) - Exercise/Conversion
Restricted Stock Unit
2023-02-14−181→ 1,134 total→ Common Stock (181 underlying) - Exercise/Conversion
Restricted Stock Unit
2023-02-14−162→ 972 total→ Common Stock (162 underlying)
Holdings
- 100(indirect: By Spouse)
Common Stock
Footnotes (12)
- [F1]Represents the weighted average price of the shares sold ranging from a low of $505.00 to a high of $505.225 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- [F10]Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023.
- [F11]Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- [F12]Not applicable.
- [F2]Represents the weighted average price of the shares sold ranging from a low of $504.49 to a high of $504.75 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- [F3]Represents the weighted average price of the shares sold ranging from a low of $503.43 to a high of $504.375 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- [F4]Represents the weighted average price of the shares sold ranging from a low of $502.42 to a high of $503.38 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- [F5]The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
- [F6]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019.
- [F7]Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020.
- [F8]Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021.
- [F9]Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022.
Documents
Issuer
IDEXX LABORATORIES INC /DE
CIK 0000874716
Entity typeother
Related Parties
1- filerCIK 0001740719
Filing Metadata
- Form type
- 4
- Filed
- Feb 15, 7:00 PM ET
- Accepted
- Feb 16, 6:56 PM ET
- Size
- 35.2 KB